Clinical trial for Primary Progressive Aphasia(PPA)
Official title Remotely-supervised Neuromodulation in PPA
ClinicalTrials.gov ID: NCT07260253
What this study is testing
- What it's testing
- The study wants to see if remote brain stimulation combined with virtual speech therapy is doable and if it improves communication compared to sham stimulation. It also looks at brain features that might predict who benefits.
- Who it's for
- Adults diagnosed with logopenic variant primary progressive aphasia.
- What's involved
- Participants will do video‑based speech‑language therapy, receive either real or placebo transcranial direct current stimulation at home under remote supervision, and complete language, cognitive tests and brain imaging before and after treatment.
- Time commitment
- The trial lasts several weeks, with regular virtual therapy sessions, daily home stimulation, and a few in‑person testing visits.
You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Meets diagnostic criteria for primary progressive aphasia (PPA)
- Meets diagnostic criteria for logopenic variant PPA
- Attains score of 15 or higher on the Mini-Mental State Examination
- Has adequate hearing and vision (with hearing or vision aids, if needed)
- Is able to travel to research site and undergo MRI brain scan
You likely can't join if
- Speech and language deficits better accounted for by another neurological disorder
- Does not meet diagnostic criteria for logopenic variant PPA
- Scores less than 15 on the Mini-Mental State Examination
- Does not have a study partner who can co-enroll in the study
- Has contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture
- Has a history of stroke, epilepsy, or significant brain injury
See the full eligibility criteria
- Meets diagnostic criteria for primary progressive aphasia (PPA)
- Meets diagnostic criteria for logopenic variant PPA
- Attains score of 15 or higher on the Mini-Mental State Examination
- Has adequate hearing and vision (with hearing or vision aids, if needed)
- Is able to travel to research site and undergo MRI brain scan
- Has access to high speed internet and basic experience using a computer and the internet
- Is a fluent speaker of English
- Has a study partner who can co-enroll in the study, attend pre-treatment training at the research site, and be present for teleconference meetings, as needed
- Speech and language deficits better accounted for by another neurological disorder
- Does not meet diagnostic criteria for logopenic variant PPA
- Scores less than 15 on the Mini-Mental State Examination
- Does not have a study partner who can co-enroll in the study
- Has contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture; History of severe or frequent migraines; Metallic implant in head or any metal in head
- Has a history of stroke, epilepsy, or significant brain injury
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
- Austin, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States; Austin, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.